Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Polymerase-mediated ultramutagenesis in mice produces diverse cancers with high mutational load
Hao-Dong Li, Ileana Cuevas, Musi Zhang, Changzheng Lu, Md Maksudul Alam, Yang-Xin Fu, M. James You, Esra A. Akbay, He Zhang, Diego H. Castrillon
Hao-Dong Li, Ileana Cuevas, Musi Zhang, Changzheng Lu, Md Maksudul Alam, Yang-Xin Fu, M. James You, Esra A. Akbay, He Zhang, Diego H. Castrillon
View: Text | PDF
Research Article Genetics Oncology

Polymerase-mediated ultramutagenesis in mice produces diverse cancers with high mutational load

  • Text
  • PDF
Abstract

Mutations underlie all cancers, and their identification and study are the foundation of cancer biology. We describe what we believe to be a novel approach to mutagenesis and cancer studies based on the DNA polymerase ε (POLE) ultramutator phenotype recently described in human cancers, in which a single amino acid substitution (most commonly P286R) in the proofreading domain results in error-prone DNA replication. We engineered a conditional PoleP286R allele in mice. PoleP286R/+ embryonic fibroblasts exhibited a striking mutator phenotype and immortalized more efficiently. PoleP286R/+ mice were born at Mendelian ratios but rapidly developed lethal cancers of diverse lineages, yielding the most cancer-prone monoallelic model described to date, to our knowledge. Comprehensive whole-genome sequencing analyses showed that the cancers were driven by high base substitution rates in the range of human cancers, overcoming a major limitation of previous murine cancer models. These data establish polymerase-mediated ultramutagenesis as an efficient in vivo approach for the generation of diverse animal cancer models that recapitulate the high mutational loads inherent to human cancers.

Authors

Hao-Dong Li, Ileana Cuevas, Musi Zhang, Changzheng Lu, Md Maksudul Alam, Yang-Xin Fu, M. James You, Esra A. Akbay, He Zhang, Diego H. Castrillon

×

Figure 5

Characterization of other lethal malignancies observed in PoleP286R/+ mice.

Options: View larger image (or click on image) Download as PowerPoint
Characterization of other lethal malignancies observed in PoleP286R/+ mi...
(A) Lung adenocarcinoma with extensive infiltration (inset) and invasion through pleura. (B) Mammary gland carcinoma, with focus of ductal carcinoma in situ (DCIS) and invasive carcinoma (left). (C) Skin with invasive SCC, ranging from well differentiated to poorly differentiated. (D) Pancreatic adenocarcinoma; area shown is well differentiated. (E) Invasive endometrioid adenocarcinoma (left); inset shows low-magnification scan (actual size) of H&E-stained slide demonstrating endometrial adenocarcinoma in the left uterine horn and a benign hemangioma (ha) on the right horn. The endometrioid adenocarcinoma invaded through myometrium and uterine serosa into adjacent structures such as oviducts. (F) Colonic adenocarcinoma. (G) Histiocytic “sarcoma” in the liver (of hematopoietic origin/histiocytic differentiation). This tumor was widely disseminated and replaced more than 50% of the liver. (H) Angiosarcoma of the colon; entrapped colonic gland is visible in the upper right-hand corner. (I) Osteosarcoma with mineralized osteoid matrix. IHC stains are shown as insets in A, C, and G for selected lineage-specific markers confirming histotypes (TTF-1, ER, p63, and F4/80; ×50 magnification for all).Scale bars: 200 μm (A and C), 50 μm (B and D–I).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts